THE NEXT GREAT ADVANCEMENT IN ACUTE DES PERFORMANCE
FOR SUPERIOR DELIVERABILITY:
FROM 2.0–3.25 mm2:
IN SMALL VESSELS:
EXCELLENT RESULTS IN SMALL VESSELS AT 12 MONTHS4
PROVEN SMALL-VESSEL CLINICAL PERFORMANCE IN ALMOST 4000 PATIENTS STUDIED
Bench test data on file at Medtronic. May not be indicative of clinical performance. Testing performed on smallest diameters available for Abbott Xience Alpine™*, Biotronik Orsiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, and Medtronic Resolute Onyx™ coronary stents.
The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Do not dilate the 2.0- mm stents to greater than 3.25 mm. Postdilatation required for overexpansion.
Based on bench test data. May not be indicative of clinical performance.
Price et al. JACC Cardiovascular Interventions. 2017;10(14):1381–1388. Study only powered for TLF clinical endpoint. Rates are taken from KM estimates.
Serra et al. TCT 2014. Post-hoc RESOLUTE Pooled analysis was not powered for the analysis shown. RESOLUTE FIM, RESOLUTE All Comers, RESOLUTE International, RESOLUTE US, RESOLUTE US 38mm, RESOLUTE Japan, RESOLUTE China RCT, RESOLUTE China Registry, RESOLUTE Asia, RESOLUTE Japan SVS
© 2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.